Here are five takeaways from the report:
- The amount of private, capital-backed healthcare deals has significantly declined.
- There has been a higher level of capital invested in 2022 so far, mainly because of Bain Capital and Hellman & Friedman’s $17 billion buyout of health tech company Athenahealth in the first quarter.
- Pharmaceuticals, biotech and health tech have become more popular, with pharmaceuticals and health tech accounting for more than 70 percent of total capital investments. Pharmaceuticals came in at 37 percent and health tech at 36 percent.
- Despite a lower volume of deals, the first half of 2022 could outperform the first half of 2021 because most capital in 2021 was invested in the second half of the year.
- Expected trends include investors becoming more rigorous in their approach to maximizing valuations and startups seeing a need to moderate funding expectations and to partner with other companies. Additionally, with the size and capital of the current market, the main way for investors to generate return will be through on-the-ground valuation.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
